Managing oligoprogressive NSCLC during immune checkpoint inhibitor therapy

17 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Umair Mahmood, BSc, MSc, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the management of oligoprogressive disease (OPD) in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors, highlighting the potential benefits of local treatments such as radiation. The study identified factors associated with improved outcomes, including visceral OPD lesions, intermediate to high-dose radiation, and local response to radiation, which can inform clinical decisions on optimal treatment strategies. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Categoria
Oncology
Commenta per primo questo video.

Prossimo